VC: San Diego biotechs raise $143M



San Diego biotechs raise $143M.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Verus Pharmaceuticals
San Diego

$78M/$20M loan
first round

Domain Associates, Prospect Venture Partners

Verus plans to in-license pediatric drugs and move quickly to Phase III.

Somaxon Pharmaceuticals
San Diego

$65M
third round

MPM Capital Partners

Somaxon has an insomnia drug -- Silenor -- in Phase III.

Osiris Therapeutics
Baltimore

$50M
undisclosed

Friedli Corporate

Osiris is in a race to become the first biotech to commercialize stem cell products.

Ziopharm
Charlestown, MA

$18.1M
first round

Paramount BioCapital

Ziopharm is looking to in-license cancer products.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.